Ignite Creation Date:
2024-05-06 @ 3:05 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04512378
Status:
SUSPENDED
Last Update Posted:
2024-06-03
First Post:
2020-08-07
Brief Title:
Group CBT for Intolerance of Uncertainty
Sponsor:
University of Manitoba
Organization:
University of Manitoba
Study Overview
Official Title:
Facing the Unknown Together Piloting a Group-based CBT Protocol for Intolerance of Uncertainty
Status:
SUSPENDED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Principal Investigator medical maternity leave
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Generalized anxiety disorder GAD is a debilitating condition involving excessive and uncontrollable worry and anxiety Difficulty tolerating the uncertainties of life known as intolerance of uncertainty IU has been shown to be key in the development and maintenance of GAD symptoms A new streamlined cognitive-behavioural treatment that targets IU has been shown to be effective in at reducing GAD symptoms IU and general psychopathology when delivered one-on-one with a therapist as shown in a recently published pilot study The individual format of this treatment is now being evaluated in a randomized controlled trial RCT The overall objective of this study is to pilot test a group version of the treatment protocol to determine if a future RCT of this group treatment is both warranted and feasible We will also conduct a preliminary investigation into the group treatments efficacy A total of two pilot groups N 12-20 will be conducted with participants recruited from two clinical hospital sites in Winnipeg Manitoba Canada The group treatment protocol will be delivered over the course of 12 weekly therapy sessions Participants will complete assessment measures at pretreatment posttreatment and at a 3-month follow-up point All assessments and treatment sessions will be conducted virtually via videoconferencing platform due to ongoing COVID-19 pandemic restrictions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None